Zoledronic acid does not affect insulin resistance in men receiving androgen deprivation therapy: a prespecified secondary analysis of a randomised controlled trial

Zoledronic acid does not affect insulin resistance in men receiving androgen deprivation therapy: a prespecified secondary analysis of a randomised controlled trial

Background: Animal studies suggest that undercarboxylated osteocalcin may improve insulin sensitivity via its effect on testicular testosterone production. Human studies have been conflicting. Men undergoing androgen deprivation therapy (ADT) for prostate cancer experience profound hypogonadism resu...

Full description

Bibliographic Details
Main Authors:	Ada S. Cheung, Rudolf Hoermann, Jasmine Zhu, Daryl Lim Joon, Jeffrey D. Zajac, Mathis Grossmann
Format:	Article
Language:	English
Published:	SAGE Publishing 2021-05-01
Series:	Therapeutic Advances in Endocrinology and Metabolism
Online Access:	https://doi.org/10.1177/20420188211012118

Similar Items

Efficacy of zoledronic acid in older prostate cancer patients undergoing androgen deprivation therapy
by: Ippei Kojima, et al.
Published: (2019-12-01)

Androgen Deprivation Therapy Toxicity and Management for Men Receiving Radiation Therapy
by: Matthew E. Johnson, et al.
Published: (2012-01-01)

Risk of Comorbidities in Advanced Prostate Cancer Patients Receiving Androgen Deprivation Therapy
by: Olivia Rachel Hwang, et al.
Published: (2018)

Lacrimal sac adenocarcinoma managed with androgen deprivation
by: David H. Abramson, et al.
Published: (2020-09-01)

Using Switching Linear Systems to Reach a Prespecified Traget
by: A. Benmerzouga
Published: (1997-12-01)

Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer
by: Richard Shore, et al.
Published: (2021-06-01)

Risk of ischemic stroke in patients with prostate cancer receiving androgen deprivation therapy in Taiwan
by: Kuang-Ming Liao, et al.
Published: (2019-12-01)

Decreased Risk of Renal Calculi in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer
by: Chien-Yu Lin, et al.
Published: (2020-03-01)

A pilot study of exercise in men with prostate cancer receiving androgen deprivation therapy
by: Lee C, et al.
Published: (2012-03-01)

Male androgen deficiency: a multisystem syndrome
by: Mathis Grossmann, et al.
Published: (2014-02-01)

Insulin resistance in transgender individuals correlates with android fat mass
by: Ingrid Bretherton, et al.
Published: (2021-01-01)

A randomised controlled trial to evaluate the efficacy of a 6 month dietary and physical activity intervention for prostate cancer patients receiving androgen deprivation therapy
by: Haseen Farhana, et al.
Published: (2010-08-01)

Patients receiving androgen deprivation therapy for prostate cancer have an increased risk of depressive disorder.
by: Shiu-Dong Chung, et al.
Published: (2017-01-01)

Risk factors for bone loss with prostate cancer in Korean men not receiving androgen deprivation therapy
by: Sun-Ouck Kim, et al.
Published: (2009-04-01)

Self-reported exercise and risk of osteoporosis in prostate cancer patients receiving androgen deprivation therapy
by: Mennen-Winchell, Lori J.
Published: (2015)

Identifying potential treatment effect modifiers of the effectiveness of chiropractic care to infants with colic through prespecified secondary analyses of a randomised controlled trial
by: Lise Vilstrup Holm, et al.
Published: (2021-04-01)

Prognostic significance of diabetes mellitus and dyslipidemia in men receiving androgen-deprivation therapy for metastatic prostate cancer
by: Yu Hirata, et al.
Published: (2019-12-01)

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
by: Shtutman Michael, et al.
Published: (2010-04-01)

Zoledronic acid combined with androgen-deprivation therapy may prolong time to castration-resistant prostate cancer in hormone-naïve metastatic prostate cancer patients – A propensity scoring approach
by: Kazuhiro Nagao, et al.
Published: (2016-01-01)

CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer
by: Justin H. Hwang, et al.
Published: (2019-11-01)

Mechanisms for zoledronic acid- and glucose deprivation-induced cell death in human breast cancer cells
by: Li-Lin Hsu, et al.
Published: (2018)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
by: Shimajiri Shohei, et al.
Published: (2011-05-01)

Assumption Checking Before Application of the Prespecified QT Linear Mixed Effect Model is Essential
by: Dinko Rekić, et al.
Published: (2020-07-01)

Adaptive Tracking Control Approach With Prespecified Accuracy for Uncertain Nonlinearly Parameterized Switching Systems
by: Jing Li, et al.
Published: (2018-01-01)

The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV
by: Cannon, C.P, et al.
Published: (2022)

Androgen deprivation therapy and the risk of subsequent keratitis
by: Dai-Wei Liu, et al.
Published: (2021-01-01)

Investigation of Fall Risk and a Herpes Zoster Attack in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer
by: Fang-Jen Wu, et al.
Published: (2018)

Efficacy of Androgen Deprivation Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel-Based Chemotherapy
by: Kyungchan Min, et al.
Published: (2020-04-01)

Strength and Balance Training for Preventing Falls in Prostate Cancer Patients Receiving Androgen Deprivation Therapy: Case Report
by: Parivash Jamrasi, et al.
Published: (2020-11-01)

Efficacy of walking exercise in promoting cognitive-psychosocial functions in men with prostate cancer receiving androgen deprivation therapy
by: Lee C, et al.
Published: (2012-07-01)

Depression, Anxiety, and Patterns of Mental Health Care Among Men With Prostate Cancer Receiving Androgen Deprivation Therapy
by: Bohnert, A.S.B, et al.
Published: (2022)

Dual X-ray Absorptiometry Screening for Men Receiving Androgen Deprivation Therapy-Hiding in Plain (Film) Sight
by: Kamran, S.C, et al.
Published: (2022)

Inherited Variants in Wnt Pathway Genes Influence Outcomes of Prostate Cancer Patients Receiving Androgen Deprivation Therapy
by: Jiun-Hung Geng, et al.
Published: (2016-11-01)

Association analysis of Wnt pathway gene on clinical outcomes in prostate cancer patients receiving androgen-deprivation therapy
by: Jiun-Hung Geng, et al.
Published: (2015)

A cost-outcome analysis of androgen deprivation therapy and androgen deprivation therapy combine radiotherapy for locally advanced prostate cancer
by: Wei-Na Wang, et al.
Published: (2011)

Androgen receptor splice variant 7 detected by immunohistochemical is an independent poor prognostic marker in men receiving adjuvant androgen-deprivation therapy after radical prostatectomy
by: Wei Ouyang, et al.
Published: (2021-03-01)

Androgen deprivation-induced senescence promotes outgrowth of androgen-refractory prostate cancer cells.
by: Dominick G A Burton, et al.
Published: (2013-01-01)

Prostate cancer incidence under androgen deprivation: A nationwide cohort study in trans women receiving hormone treatment
by: I. de Nie, et al.
Published: (2020-07-01)

Development and Initial Validation of the Novel Scale for Assessing Quality of Life of Prostate Cancer Patients Receiving Androgen Deprivation Therapy
by: Yao-Jun Dun, et al.
Published: (2017-01-01)

Predictive clinical indicators of biochemical progression in advanced prostate cancer patients receiving Leuplin depot as androgen deprivation therapy.
by: Chien-Hua Chen, et al.
Published: (2014-01-01)